Cetera Investment Advisers’s AbCellera Biologics ABCL Stock Holding History

Cetera Investment Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.4K	Buy	11,298 +70	+0.6%	+$252	﹤0.01%	4608
2025 Q4	$38.4K	Sell	11,228 -47	-0.4%	-$210	﹤0.01%	4537
2025 Q3	$56.7K	Sell	11,275 -2,216	-16%	-$9.77K	﹤0.01%	4415
2025 Q2	$46.3K	Sell	13,491 -763	-5%	-$1.9K	﹤0.01%	3980
2025 Q1	$31.8K	Buy	14,254 +448	+3%	+$1.28K	﹤0.01%	3893
2024 Q4	$40.5K	Sell	13,806 -71	-0.5%	-$198	﹤0.01%	3670
2024 Q3	$36.1K	Buy	+13,877	New	+$38.5K	﹤0.01%	3620
2024 Q2	–	Sell	-22,877	Closed	-$104K	–	3725
2024 Q1	$104K	Buy	+22,877	New	+$117K	﹤0.01%	3497

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cetera Investment Advisers's ABCL Position: Q1 2026 in Review

Cetera Investment Advisers increased its AbCellera Biologics (ABCL) stake by 0.62% in Q1 2026, buying an estimated $252 and bringing the position to 11,298 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4608.

Cetera Investment Advisers first reported a position in ABCL in Q1 2024 and has held it in 8 quarters since. The position peaked at $104K in Q1 2024. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Cetera Investment Advisers held 11,298 shares of AbCellera Biologics worth $39.4K as of Q1 2026.
Cetera Investment Advisers bought 70 AbCellera Biologics shares in Q1 2026, an estimated $252.
AbCellera Biologics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #4608 holding.
Cetera Investment Advisers first reported a position in AbCellera Biologics in Q1 2024 and has held it in 8 quarters since.
Cetera Investment Advisers's AbCellera Biologics position peaked at $104K in Q1 2024.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.